10035499Healing the Gap in Wound TechnologyClosedCollaborative R&DInnovate UKThere is an urgent need for innovate products in the chronic wound care market due to an increasing prevalence of chronic wounds and a lack of confidence in existing technologies. There were an estimated 3.8 million patients with a wound managed by the NHS in 2017/18 with an increase in prevalence of 71% between 2012/13 and 2017/18\. There are several antibiofilm wound treatments on the market however the dressing market is dominated by silver technology. Clinicians and nurses on the front line do not have time to appropriately manage chronic wounds which prolongs their healing, increasing the burden on health care systems. Key stakeholders believe there are huge opportunities to disrupt this market. Hybrisan are established experts in antimicrobial and antibiofilm technology, however require further resource to introduce this technology into the chronic wound sector. There is an opportunity to disrupt a market dominated by silver. During this project Hybrisan will develop their independently proven antibiofilm and antimicrobial technology into a functional nanofibre for the chronic wound care market for use with existing wound dressing platforms.